NRG-CC013: A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation

Objective

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect of chemoradiation that can cause pain and difficulty swallowing. Usual management of these side effects typically consists of using mouth rinses and pain medications during treatment and for several weeks after completion of treatment. BMX-001 neutralizes harmful substances in the body, preventing damage to macromolecules such as DNA and minimizes free radical-related toxicity in normal tissues. Adding BMX-001 to usual symptom management may be more effective than usual symptom management alone at reducing oral mucositis in patients receiving chemoradiation for head and neck cancer.

National Clinical Trial (NCT) Number: 06532279

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT06532279

Location: Essentia Health Cancer Centers

 

Research Study Categories

• Adult Oncology Studies

Specialties

• Head and Neck Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]